In the BioHarmony Drug Report Database

"Preview" Icon

Risdiplam

Evrysdi (risdiplam) is a small molecule pharmaceutical. Risdiplam was first approved as Evrysdi on 2020-08-07. It has been approved in Europe to treat spinal muscular atrophy. Evrysdi’s patents are valid until 2035-05-11 (FDA).

 

Trade Name

 

Evrysdi
 

Common Name

 

risdiplam
 

ChEMBL ID

 

CHEMBL4297528
 

Indication

 

spinal muscular atrophy
 

Drug Class

 

Survival motor neurin SMN1 and SMN2 splicing modulators

Image (chem structure or protein)

Risdiplam structure rendering